Novo Nordisk tries to tackle Ablynx and bring it into the fold with a $3B buyout offer, but the biotech keeps saying no
Playing a hot hand with a promising late-stage asset and a newly completed $200 million IPO, Ablynx has waved away two bids by Novo Nordisk …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
